Pharma

Reverse-phase silica media for GLP‑1 and other peptides; available in C8 and C18 chemistries for high-resolution separations and integration with AmberChrom polymeric resins from development to manufacturing.

VYVGART sales up 54% YoY; sBLA filings and Phase‑3 readouts scheduled through Dec 2026–2027; cash $3.7B and combined R&D+SG&A guide ≈$4B for 2026.

Group sales +6% (CER) in first nine months; Q3 +7% (CER)/+8% CHF. Pharmaceuticals drove growth, diagnostics up despite China pricing reforms. 2026 outlook confirmed.

EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.

Phase III fenebrutinib data show reduced chronic active MS lesions and a 55% ARR cut; Ocrevus shows durable pediatric and older-adult control; Enspryng supports MOGAD attack reduction.

Post hoc REDEFINE 1 analyses found once‑weekly cagrilintide/semaglutide produced large weight and waist‑circumference reductions across menopausal stages; main adverse events were gastrointestinal. FDA decision expected Q4 2026.

Phase 3 CROSSING found TEZSPIRE produced sustained histologic remission, reduced dysphagia scores and achieved endoscopic remission through week 52 in adolescents and adults with eosinophilic esophagitis.

FDA approves a six-month antisense-oligonucleotide therapy with option for self-administration; phase III showed 19% functional cure in patients with HBsAg ≤3000 IU/ml.

Treating to corticosteroid-free disease clearance with vedolizumab lengthened time to first ulcerative colitis complication and cut complication risk by about 70%.

Phase 3 ALKIVIA shows clinically meaningful, rapid improvements in IMNM and dermatomyositis, seen by Week 4 and sustained to Week 52; primary endpoint met (TIS +15.4).